

Special Issue

High-Grade Serous Ovarian Cancer

Message from the Guest Editor

Among ovarian cancers, high-grade serous ovarian cancer (HGSOC) is the most frequent histology with the poorest prognosis. In most cases, HGSOC is at an advanced stage 3–4 at the time of diagnosis, and the treatment policy requires not only surgery but also pharmacotherapy. Approximately 70% of HGSOCs respond to platinum combination pharmacotherapy, but once they have responded, many relapse and become drug-resistant and fatal. In recent years, omics analysis such as transcriptome analysis and whole-genome analysis of HGSOC has been performed, and research on the relationship with susceptibility to drug therapy has been progressing. This Special Issue calls for research on drug sensitivity or resistance, individualized treatment, and omics analysis of HGSOC.

Guest Editor

Prof. Dr. Noriomi Matsumura

Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama, Osaka 589-8511, Japan

Deadline for manuscript submissions

closed (30 November 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/45270

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)